Search results
Results from the WOW.Com Content Network
The Center for Cell and Gene Therapy has the largest academic GMP facility in the world, with 8,600 square feet of Class 10,000 (ISO7) cleanroom space. The GMP Gene Vector Lab produces clinical grade vectors for use in Phase I/II trials, while the GMP Clinical Research Lab prepares patient components for clinical trials.
The Center for Stem Cell and Regenerative Medicine (CSCRM) is a medical research institution specializing in stem cell and other cell therapy research and treatments, located in Cleveland, Ohio. They specialize in basic and clinical research programs, biomedical and tissue engineering programs, and the development and administration of new ...
In 2014, the center — along with the Sue & Bill Gross Stem Cell Research Center at University of California, Irvine — received an $8-million grant from CIRM to establish a CIRM Alpha Stem Cell Clinic "center of excellence" to conduct clinical trials for investigational stem cell therapies and provide critical resources and expertise in ...
PTC Therapeutics (PTCT) gets an FDA sanction to begin a phase II/III study on its DHODH inhibitor PTC299 as a potential treatment of COVID-19. The study will start in the United States shortly.
AV-COVID-19 AIVITA Biomedical, Inc., Ministry of Health (Indonesia) United States, Indonesia Dendritic cell vaccine (autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein, with or without GM-CSF) Phase I–II (202) [187] [188] Adaptive. Dec 2020 – Feb 2022, Indonesia (phase I), United States (phase I/II ...
CHICAGO, Aug 14 (Reuters) - U.S. government scientists have begun efforts to manufacture a strain of the novel coronavirus that could be used in human challenge trials of vaccines, a controversial ...
This is a list of countries by stem cell research trials for the purpose of commercializing treatments as of June 2020, using data from ClinicalTrials.gov. [ 1 ] Rank
The Food and Drug Administration (FDA) approved the first clinical trial in the United States involving human embryonic stem cells on January 23, 2009. Geron Corporation, a biotechnology firm located in Menlo Park, California, originally planned to enroll ten patients with spinal cord injuries to participate in the trial.